Expansion opportunity SkylineDx has recently expanded offices in the United States, indicating a growing commercial footprint and increased potential to collaborate with US-based clinics, hospitals, and dermatology/oncology centers for Merlin CP-GEP and other molecular diagnostic services.

FDA recognition Receiving Breakthrough Device designation for Merlin CP-GEP signals a strong regulatory pathway and potential faster adoption; leverage this to engage payers and early-adopter institutions seeking differentiated precision diagnostics.

Clinical programs New Guideline-Informed Risk Assessment Initiative and ongoing presentations at dermatology and melanoma conferences show a commitment to clinically integrated tools; identify partners in surgical oncology and multidisciplinary teams for risk assessment and personalized treatment planning.

Market focus Strong emphasis on cutaneous squamous cell carcinoma and melanoma, suggesting primary sales opportunities with dermatology networks, cancer centers, and pathology labs seeking genomic-guided decision support.

Diverse growth Recent awards and broad engagement in conferences indicate momentum in oncology diagnostics beyond dermatology; pursue collaborations with research centers and early-adopter biotech and pharma partners for co-development and commercialization.